Innovative radioisotope therapy for patients with neuroendocrine tumors using an alpha (225Ac) emitter labeled somatostatin analog - octreotate. A promising new treatment for advanced, progressive neuroendocrine neoplasms

Neuroendocrine neoplasms (NENs) constitute a diverse group of solid tumors of various locations and account for approximately 2% of all malignancies. In 30% of cases, NENs occur in locations other than the gastrointestinal tract: lungs, bronchi, thymus, thyroid, ovaries. The current incidence rate for these diseases is approximately 35 cases per 100 000 inhabitants on average..However, epidemiological studies show a significant increase in the occurrence of this group of diseases. The most promising therapy of non-resectable metastatic changes, especially when other available treatment methods are ineffective, is peptide receptor radionuclide therapy (PRRT) based on somatostatin analogs conjugated with β emitters – 90Y and 177Lu. Unfortunately, in cases of tumor recurrence, neoplastic changes usually show resistance to β radiation, despite the retained increased expression of somatostatin receptors. First trials with another 225Ac-labeled somatostatin analog DOTATOC showed excellent results during the five-year period of clinical observation. Therefore, a novel study using DOTATATE bioconjugate labeled with the alpha emitter - 225Ac was conducted to develop a more effective and safe therapy. In this paper we report on the therapy using an alpha emitter - 225Ac, which to our knowledge is so far unprecedented in Poland.

BUDLEWSKI Tadeusz;  KROL Zbigniew;  BRUCHERTSEIFER Frank;  MAJKOWSKA-PILIP Agnieszka;  MORGENSTERN Alfred;  WIERZBA Waldemar; 

2022-12-16

MEDYCYNA PRAKTYCZNA SP K SP ZOO

JRC128875

0032-3772 (online),   

https://publications.jrc.ec.europa.eu/repository/handle/JRC128875,   

10.20452/pamw.16275 (online),